Loading cancer entity…
Loading cancer entity…
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 |
| Mar 2, 2026 |
| clinicaltrials |
| NCT04794127 | Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.(TRABEPIO) | completed | Phase 2 | 10 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT02249949 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 15 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02978859 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | completed | Phase 2 | 70 | Leiden University Medical CenterOTHER | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02247544 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma(TRAVELL) | completed | Phase 2 | 105 | Italian Sarcoma GroupNETWORK | 1 | Nov 1, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | completed | Phase 2 | 52 | Grupo Espanol de Investigacion en SarcomasOTHER | 2 | Jul 23, 2020 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01209598 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | completed | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01506596 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | completed | Phase 2 | 42 | Vector OncologyOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | completed | Phase 2 | 271 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 8 | Sep 8, 2014 | clinicaltrials |
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | completed | Phase 2 | 29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 3 | May 7, 2014 | clinicaltrials |
| NCT00400569 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 28, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials